Related references
Note: Only part of the references are listed.Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models
Konstantin H. Dragnev et al.
CANCER PREVENTION RESEARCH (2011)
Low-Dose Weekly Docetaxel Is as Tolerable as Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer
Fu-Tsai Chung et al.
CHEMOTHERAPY (2011)
Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study)
Fumio Imamura et al.
CHEMOTHERAPY (2011)
Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non-Small-Cell Lung Cancer
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer
J. Michels et al.
ANNALS OF ONCOLOGY (2010)
A Phase II Study Directed by a Clinical Pathway for Carboplatin and Weekly Paclitaxel in Previously Untreated Patients with Unresectable Non-Small Cell Lung Cancer
Kiyoshi Komuta et al.
CHEMOTHERAPY (2010)
ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature
Yanping Luo et al.
ANTI-CANCER DRUGS (2009)
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer
Christopher G. Azzoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors
Elizabeth Fox et al.
CLINICAL CANCER RESEARCH (2008)
A phase II study of ABT-751 in patients with advanced non-small cell lung cancer
Ann M. Mauer et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim et al.
LANCET (2008)
Treatment of non-small cell lung cancer, stage IV - ACCP evidence-based clinical practice guidelines (2nd edition)
Mark A. Socinski et al.
CHEST (2007)
Evaluation of ABT-751 against childhood cancer models in vivo
Christopher L. Morton et al.
INVESTIGATIONAL NEW DRUGS (2007)
Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth
Timothy J. Jorgensen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors
Elizabeth Fox et al.
CLINICAL CANCER RESEARCH (2006)
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: Results of a phase 1 study
KR Hande et al.
CLINICAL CANCER RESEARCH (2006)
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
KWL Yee et al.
CLINICAL CANCER RESEARCH (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003
DG Pfister et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study
JA Segreti et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers
WJ Petty et al.
CLINICAL CANCER RESEARCH (2004)
Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer:: a phase III randomized trial
P Zatloukal et al.
LUNG CANCER (2003)
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group
F Fossella et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
R Rosell et al.
ANNALS OF ONCOLOGY (2002)
Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors
J Maurel et al.
ANTI-CANCER DRUGS (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: A review
C Huisman et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
FA Shepherd et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
